Access to CSL’s products CSL has a great opportunity to contribute to healthier communities through its continued supply and development of new therapies for unmet medical needs, while enabling greater access to life-saving vaccines, iron therapies, and plasma- and protein‑based therapies. Extending the reach of its therapies and vaccines means CSL can help advance equitable access across vulnerable populations and share its expertise to help build capabilities where they are needed. As CSL continues to develop and commercialise biopharmaceutical innovations that evolve the treatment paradigm, such as gene therapy, it is committed to working with governments, insurance payers, and other stakeholders to design new payment and access solutions that reflect value, and that meet the needs of individual patients and healthcare systems. CSL also continues to work with varying levels of governments, health insurance payers and other stakeholders to support timely and appropriate market entry and access, to enable patients to benefit from its therapies as quickly as possible. CSL values an ongoing dialogue with policymakers, advocacy groups, and other stakeholders to understand and respond to their needs and expectations. CSL is also a substantial supporter of, and provides, patient assistance programs and supports advocacy efforts that improve access to care and affordability. Improving access for patients with immune deficiencies CSL recognises the importance of collaborating with patient advocacy organisations to help bridge health equity gaps and provide access to medicines through resources and solutions. CSL Behring’s donation to patient advocacy organisations aligns with its overall strategic business goals and principles of general social responsibility, by funding support and education, and through advocacy that helps improve health outcomes. Over the reporting period, CSL provided funding support through charitable donations to Hereditary Angioedema International (HAEi) and the Jeffrey Model Foundation (JMF). CSL donated €500,000 to HAEi in the areas of education, technology and advocacy activities encapsulated in the four strategic pillars for HAEi, including; Member Organisation Development, ACARE: Collaboration with the Global Physician/Scientific Community, HAEi Youngster’s Community, and HAEi Initiated Data Driven Advocacy Research. In addition, the charitable donation supports HAEi’s Regional Patient Advocates (RPAs) in HAE patient identification and outreach, support, training and additional HAEi initiatives in developed and developing countries, including in Europe, Middle East, Africa, Asia Pacific, Southeastern Asia, America, South America and Mexico. CSL also donated US$550,000 to the JMF to support eleven Jeffrey Modell Diagnostics and Research Centres for Primary Immunodeficiencies. The funding support will provide comprehensive physician education and public awareness campaigns in the areas of early diagnosis, education and public health awareness around access to care, and improved quality of life. The 11 Jeffrey Modell Diagnostic and Research Centres are in developed and developing countries including Algeria, Egypt, Morocco, Tunisia, Argentina, Brazil, Mexico, Turkey, Austria, Belgium, Switzerland, Japan, China and Australia. CSL Behring has been a longstanding partner of JMF within and outside the United States. Healthier World * Limited assurance by Deloitte. Dollar value is a sub-set of CSL’s total community contributions. Does not include CSL Vifor as available data is not captured via the same method as the CSL Group. US$15.7m supporting product access across the world* 44 Limited Annual Report 2023/24
RkJQdWJsaXNoZXIy MjE2NDg3